Refine Search

Search Results -

Terms	Documents
L14 and angiogenesis	21

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L17

Refine Search

Recall Text Clear Interrupt

Search History

DATE: Friday, July 07, 2006 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L17	L14 and angiogenesis	21	L17
L16	L15 and @py>1970<=2003	51	L16
L15	L14 and zinc	97	L15
L14	thiomolybdate	382	L14
DB=USPT; PLUR=YES; OP=OR			
L13	6703050.pn.	1	L13
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L12	tetrapropylammonium adj tetrathiomolybdate	3	L12
L11	tetrabutylammonium adj tetrathiomolybdate	1	L11
L10	tetraethylammonium adj tetrathiomolybdate	3	L10
L9	tetramethylammonium adj tetrathiomolybdate	1	L9
L8	tetramethylammonium tetrathiomolybdate	23243	L8
L7	alkylammonium adj tetrathiomolybdate	1	L7
L6	alkylammonium tetrathiomolybdate	10567	L6

L5	alkylammonium adj thiomolybdate	1	L5
L4	L2 and zinc	1	L4

DB=PGPB; PLUR=YES; OP=OR

L3	US-20040259945-A1.did.	1	L3

DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR

L2	tetrapropylammonium adj tetrathiomolybdate	3	L2
L1	tetrapropylammonium adj tetrathiomolbdate	0	L1

END OF SEARCH HISTORY

Refine Search

Search Results -

Terms	Documents
L2 and zinc	1

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L4

Refine Search

Recall Text Clear Interrupt

Search History

DATE: Friday, July 07, 2006 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L4	L2 and zinc	1	L4
DB=PGPB; PLUR=YES; OP=OR			
L3	US-20040259945-A1.did.	1	L3
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L2	tetrapropylammonium adj tetrathiomolybdate	3	L2
L1	tetrapropylammonium adj tetrathiomolbdate	0	L1

END OF SEARCH HISTORY

Refine Search

Search Results -

Terms	Documents
tetrapropylammonium adj tetrathiomolybdate	3

Database: US Pre-Grant Publication Full-Text Database; US Patents Full-Text Database; US OCR Full-Text Database; EPO Abstracts Database; JPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L12

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Friday, July 07, 2006 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L12	tetrapropylammonium adj tetrathiomolybdate	3	L12
L11	tetrabutylammonium adj tetrathiomolybdate	1	L11
L10	tetraethylammonium adj tetrathiomolybdate	3	L10
L9	tetramethylammonium adj tetrathiomolybdate	1	L9
L8	tetramethylammonium tetrathiomolybdate	23243	L8
L7	alkylammonium adj tetrathiomolybdate	1	L7
L6	alkylammonium tetrathiomolybdate	10567	L6
L5	alkylammonium adj thiomolybdate	1	L5
L4	L2 and zinc	1	L4
DB=PGPB; PLUR=YES; OP=OR			
L3	US-20040259945-A1.did.	1	L3
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L2	tetrapropylammonium adj tetrathiomolybdate	3	L2
L1	tetrapropylammonium adj tetrathiomolbdate	0	L1

END OF SEARCH HISTORY

```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:sssptau125zxf

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  FEB 27   New STN AnaVist pricing effective March 1, 2006
 NEWS  4  APR 04   STN AnaVist $500 visualization usage credit offered
 NEWS  5  MAY 10   CA/CAplus enhanced with 1900-1906 U.S. patent records
 NEWS  6  MAY 11   KOREAPAT updates resume
 NEWS  7  MAY 19   Derwent World Patents Index to be reloaded and enhanced
 NEWS  8  MAY 30   IPC 8 Rolled-up Core codes added to CA/CAplus and
                   USPATFULL/USPAT2
 NEWS  9  MAY 30   The F-Term thesaurus is now available in CA/CAplus
 NEWS 10  JUN 02   The first reclassification of IPC codes now complete in
                   INPADOC
 NEWS 11  JUN 26   TULSA/TULSA2 reloaded and enhanced with new search and
                   and display fields
 NEWS 12  JUN 28   Price changes in full-text patent databases EPFULL and PCTFULL
 NEWS 13  JUl 07   Coverage of Research Disclosure reinstated in DWPI

 NEWS EXPRESS  JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  ********************************************************************
    Due to scheduled maintenance of STN on Sunday, July 9, 2006,
    some databases may not be available until 04:00 (4:00 AM)
    Eastern Daylight Time.
  ********************************************************************

* * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:11:28 ON 07 JUL 2006

=> file ca,medline,biosis,uspatfull,drugu,wpids,caplus
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                              ENTRY    SESSION
```

FULL ESTIMATED COST 0.42 0.42

FILE 'CA' ENTERED AT 16:12:33 ON 07 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 16:12:33 ON 07 JUL 2006

FILE 'BIOSIS' ENTERED AT 16:12:33 ON 07 JUL 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'USPATFULL' ENTERED AT 16:12:33 ON 07 JUL 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DRUGU' ENTERED AT 16:12:33 ON 07 JUL 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'WPIDS' ENTERED AT 16:12:33 ON 07 JUL 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'CAPLUS' ENTERED AT 16:12:33 ON 07 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s tetraalkylammonium (w) tetrathiomolybdate
L1 8 TETRAALKYLAMMONIUM (W) TETRATHIOMOLYBDATE

=> remove dup l1
DUP IS NOT VALID HERE
The DELETE command is used to remove various items stored by the system.

To delete a saved query, saved answer set, saved L-number list, SDI request, batch request, mailing list, or user-defined cluster, format, or search field, enter the name. The name may include ? for left, right, or simultaneous left and right truncation.

Examples:

```
  DELETE BIO?/Q           - delete query names starting with BIO
  DELETE ?DRUG/A          - delete answer set names ending with DRUG
  DELETE ?ELEC?/L         - delete L-number lists containing ELEC
  DELETE ANTICOAG/S       - delete SDI request
  DELETE ENZYME/B         - delete batch request
  DELETE .MYCLUSTER       - delete user-defined cluster
  DELETE .MYFORMAT        - delete user-defined display format
  DELETE .MYFIELD         - delete user-defined search field
  DELETE NAMELIST MYLIST - delete mailing list
```

To delete an ordered document or an offline print, enter its number.

Examples:

```
  DELETE P123001C         - delete print request
  DELETE D134002C         - delete document order request
```

To delete an individual L-number or range of L-numbers, enter the L-number or L-number range. You may also enter DELETE LAST followed by a number, n, to delete the last n L-numbers. RENUMBER or NORENUMBER may also be explicitly specified to override the value of SET RENUMBER.

Examples:

```
  DELETE L21             - delete a single L-number
  DELETE L3-L6           - delete a range of L-numbers
  DELETE LAST 4          - delete the last 4 L-numbers
  DELETE L33-            - delete L33 and any higher L-number
  DELETE -L55            - delete L55 and any lower L-number
  DELETE L2-L6 RENUMBER - delete a range of L-numbers and
                          renumber remaining L-numbers
  DELETE RENUMBER        - renumber L-numbers after deletion of
                          intermediate L-numbers
```

Entire sets of saved items, SDI requests, batch requests, user-defined items, or E-numbers can be deleted.

Examples:

```
  DELETE SAVED/Q - delete all saved queries
  DELETE SAVED/A - delete all saved answer sets
  DELETE SAVED/L - delete all saved L-number lists
  DELETE SAVED   - delete all saved queries, answer sets,
                   and L-number lists
  DELETE SAVED/S - delete all SDI requests
  DELETE SAVED/B - delete all batch requests
  DELETE CLUSTER - delete all user-defined clusters
  DELETE FORMAT  - delete all user-defined display formats
  DELETE FIELD   - delete all user-defined search fields
  DELETE SELECT  - delete all E-numbers
  DELETE HISTORY - delete all L-numbers and restart the
                   session at L1
```

To delete an entire multifile SDI request, enter DELETE and the name of the request. To delete a component from the multifile SDI, enter DELETE and the name of the component.

```
=> d l1 1-8 bib, ab

L1   ANSWER 1 OF 8  CA  COPYRIGHT 2006 ACS on STN
AN   140:139472  CA
TI   Tetrapropylammonium tetrathiomolybdate and related compounds for
     anti-angiogenic therapies
IN   Brewer, George J.; Merajver, Sofia D.; Coucouvanis, Dimitri
PA   The University of Michigan, USA; Univ Michigan
SO   PCT Int. Appl., 140 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 2004009072         A2    20040129    WO 2003-US22914         20030723
     WO 2004009072         A3    20040408
     WO 2004009072         B1    20040708
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
```

	CA 2493341	AA	20040129	CA 2003-2493341	20030723
	AU 2003261222	A1	20040209	AU 2003-261222	20030723
	US 2004259945	A1	20041223	US 2003-625839	20030723
	BR 2003012845	A	20050607	BR 2003-12845	20030723
	EP 1539131	A2	20050615	EP 2003-765921	20030723
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1688303	A	20051026	CN 2003-820746	20030723
	JP 2005538093	T2	20051215	JP 2004-523295	20030723
	ZA 2005001162	A	20050905	ZA 2005-1162	20050209
	NO 2005000902	A	20050419	NO 2005-902	20050218
PRAI	US 2002-397804P	P	20020723		
	WO 2003-US22914	W	20030723		

AB Disclosed are copper-binding compds. with improved properties and methods of using such compds. in the prevention and treatment of angiogenic diseases, such as cancer. Advantages of the invention include the enhanced stability of the compds., which is achieved without reduction in efficacy. Pharmaceutical compns., therapeutic kits and combination treatment methods and uses are also provided.

L1 ANSWER 2 OF 8 CA COPYRIGHT 2006 ACS on STN
AN 136:209573 CA
TI Synthesis of tetraalkylammonium thiometallates in aqueous solution
AU Alonso, G.; Yang, J.; Siadati, M. H.; Chianelli, R. R.
CS Centro de Investigacion en Materiales Avanzados, Departamento de Catalisis, Chihuahua, Mexico City, Mex.
SO Inorganica Chimica Acta (2001), 325(1,2), 193-197
CODEN: ICHAA3; ISSN: 0020-1693
PB Elsevier Science S.A.
DT Journal
LA English
AB An aqueous solution method for the preparation of tetraalkylammonium thiometallates
(R4N)2MS4 (R = pentyl or hexyl and, M = Mo or W) is reported. The one-step rapid substitution of [NH4]+ ions from ammonium thiomolybdate (ATM) and ammonium thiotungstate (ATT) with [(pentyl)4N]+ and [(hexyl)4N]+ ions during reactions with (pentyl)4NBr and (hexyl)4NBr, resp., is described. One application for these tetraalkylammonium thiomolybdates and thiotungstates is as precursors for MoS2 and WS2 catalysts, which were used in industrial hydrodesulfurization and hydrodenitrogenation processes. The synthesized thiometallates were characterized using the spectroscopic techniques FTIR, UV and, NMR (13C NMR) for determining their chemical
structures. Thermal analyses (TGA-DTA) were done to study the fragmentation and decomposition behavior of their mol. structures.
RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 3 OF 8 CA COPYRIGHT 2006 ACS on STN
AN 125:86999 CA
TI A new approach to some 1,6-dideoxy-1,6-epithio sugars
AU Driguez, Hugues; McAuliffe, C.; Stick, Robert V.; Tilbrook, D. Matthew G.; Wiliams, Spencer J.
CS Centre Recherches Macromolecules Vegetales, CERMAV-CNRS, Grenoble, 38041, Fr.
SO Australian Journal of Chemistry (1996), 49(3), 343-348
CODEN: AJCHAS; ISSN: 0004-9425
PB Commonwealth Scientific and Industrial Research Organization
DT Journal
LA English
OS CASREACT 125:86999
AB The treatment of hexopyranosyl bromides, also activated at C 6 (Br, OTs, OMs), with H2S/HCONMe2 under basic conditions gives 1,6-dideoxy-1,6-epithio sugars, e.g. I (R = N3, X = S). An analogous treatment of one

doubly activated hexopyranosyl bromide with sodium hydrogen selenide has led to a novel 1,6-dideoxy-1,6-episeleno sugars, e.g. I (R = OAc, X = Se), which displayed interesting NMR spectra. Finally, in an attempt to prepare 1,6-dideoxy 1,6-epidithio sugars, a tetraalkylammonium tetrathiomolybdate reagent was found to be the reagent of choice for converting doubly activated hexopyranosyl bromides into 1,6-dideoxy-1,6-epithio sugars.

L1 ANSWER 4 OF 8 USPATFULL on STN
AN 2004:328120 USPATFULL
TI Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
IN Brewer, George J., Ann Arbor, MI, UNITED STATES
Merajver, Sofia D., Ann Arbor, MI, UNITED STATES
Coucouvanis, Dimitri, Ann Arbor, MI, UNITED STATES
PA The Regents of The University of Michigan (U.S. corporation)
PI US 2004259945 A1 20041223
AI US 2003-625839 A1 20030723 (10)
PRAI US 2002-397804P 20020723 (60)
DT Utility
FS APPLICATION
LREP shelley p m fussey, williams morgan & amerson, 10333 richmond, suite 1100, houston, TX, 77042
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 5014
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are copper-binding compounds with improved properties and methods of using such compounds in the prevention and treatment of angiogenic diseases, such as cancer. Advantages of the invention include the enhanced stability of the compounds, which is achieved without reduction in efficacy. Pharmaceutical compositions, therapeutic kits and combination treatment methods and uses are also provided.

L1 ANSWER 5 OF 8 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
AN 2004-203433 [19] WPIDS
DNC C2004-080111
TI Composition, useful to treat/prevent disease associated with aberrant vascularization e.g. wet type macular degeneration, rheumatoid arthritis and cancer, comprises a tetraalkylammonium tetrathiomolybdate compound.
DC B05
IN BREWER, G J; COUCOUVANIS, D; MERAJVER, S D; MERAJVER, S
PA (UNMI) UNIV MICHIGAN
CYC 106
PI WO 2004009072 A2 20040129 (200419)* EN 140
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW
AU 2003261222 A1 20040209 (200450)
US 2004259945 A1 20041223 (200504)
BR 2003012845 A 20050607 (200538)
EP 1539131 A2 20050615 (200539) EN
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV MC MK NL PT RO SE SI SK TR
NO 2005000902 A 20050419 (200540)
KR 2005025976 A 20050314 (200574)
JP 2005538093 W 20051215 (200582) 97
CN 1688303 A 20051026 (200618)

MX 2005000875 A1 20051001 (200620)
ZA 2005001162 A 20051130 (200628) 138

ADT WO 2004009072 A2 WO 2003-US22914 20030723; AU 2003261222 A1 AU 2003-261222 20030723; US 2004259945 A1 Provisional US 2002-397804P 20020723, US 2003-625839 20030723; BR 2003012845 A BR 2003-12845 20030723, WO 2003-US22914 20030723; EP 1539131 A2 EP 2003-765921 20030723, WO 2003-US22914 20030723; NO 2005000902 A WO 2003-US22914 20030723, NO 2005-902 20050218; KR 2005025976 A KR 2005-701226 20050122; JP 2005538093 W WO 2003-US22914 20030723, JP 2004-523295 20030723; CN 1688303 A CN 2003-820746 20030723; MX 2005000875 A1 WO 2003-US22914 20030723, MX 2005-875 20050121; ZA 2005001162 A ZA 2005-1162 20050209

FDT AU 2003261222 A1 Based on WO 2004009072; BR 2003012845 A Based on WO 2004009072; EP 1539131 A2 Based on WO 2004009072; JP 2005538093 W Based on WO 2004009072; MX 2005000875 A1 Based on WO 2004009072

PRAI US 2002-397804P 20020723; US 2003-625839 20030723

AB WO2004009072 A UPAB: 20040318

NOVELTY - Composition (A) comprises at least one tetraalkylammonium tetrathiomolybdate compound (I) and a pharmaceutically acceptable excipient.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a kit comprising, in at least one container, at least one compound (I) and either a second, distinct therapeutic agent (II) or a component of an assay system for determining serum ceruloplasmin levels (III).

ACTIVITY - Ophthalmological; Cytostatic; Antirheumatic; Antiarthritic, Antiangiogenic.

MECHANISM OF ACTION - None given in the source material.

USE - (A) is used for treatment/prevention of a disease associated with aberrant vascularization (preferably wet type macular degeneration, rheumatoid arthritis or cancer) in an animal (preferably a human) that has or is at risk for developing the disease (claimed).

ADVANTAGE - (I) displays increased stability and shelf life, without significant loss of solubility or therapeutic efficacy. This allows the drug to be handled pharmaceutically in bulk without exquisite attention to air exclusion The stability of (I) was studied under conditions that exacerbate instability (i.e. by leaving the drug in open Petri dishes at room temperature) using a tetrathiomolybdate preparation as control. The half life of tetrapropylammonium tetrathiomolybdate under these conditions was determined to be about 180 days whereas it was about 40 days for the control.

Dwg.0/5

L1 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:80492 CAPLUS
DN 140:139472
TI Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
IN Brewer, George J.; Merajver, Sofia D.; Coucouvanis, Dimitri
PA The University of Michigan, USA; Univ Michigan
SO PCT Int. Appl., 140 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004009072	A2	20040129	WO 2003-US22914	20030723
	WO 2004009072	A3	20040408		
	WO 2004009072	B1	20040708		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2493341	AA	20040129	CA 2003-2493341	20030723
AU 2003261222	A1	20040209	AU 2003-261222	20030723
US 2004259945	A1	20041223	US 2003-625839	20030723
BR 2003012845	A	20050607	BR 2003-12845	20030723
EP 1539131	A2	20050615	EP 2003-765921	20030723
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1688303	A	20051026	CN 2003-820746	20030723
JP 2005538093	T2	20051215	JP 2004-523295	20030723
ZA 2005001162	A	20050905	ZA 2005-1162	20050209
NO 2005000902	A	20050419	NO 2005-902	20050218
PRAI US 2002-397804P	P	20020723		
WO 2003-US22914	W	20030723		

AB Disclosed are copper-binding compds. with improved properties and methods of using such compds. in the prevention and treatment of angiogenic diseases, such as cancer. Advantages of the invention include the enhanced stability of the compds., which is achieved without reduction in efficacy. Pharmaceutical compns., therapeutic kits and combination treatment methods and uses are also provided.

L1 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:855323 CAPLUS
DN 136:209573
TI Synthesis of tetraalkylammonium thiometallates in aqueous solution
AU Alonso, G.; Yang, J.; Siadati, M. H.; Chianelli, R. R.
CS Centro de Investigacion en Materiales Avanzados, Departamento de Catalisis, Chihuahua, Mexico City, Mex.
SO Inorganica Chimica Acta (2001), 325(1,2), 193-197
CODEN: ICHAA3; ISSN: 0020-1693
PB Elsevier Science S.A.
DT Journal
LA English
AB An aqueous solution method for the preparation of tetraalkylammonium thiometallates (R4N)2MS4 (R = pentyl or hexyl and, M = Mo or W) is reported. The one-step rapid substitution of [NH4]+ ions from ammonium thiomolybdate (ATM) and ammonium thiotungstate (ATT) with [(pentyl)4N]+ and [(hexyl)4N]+ ions during reactions with (pentyl)4NBr and (hexyl)4NBr, resp., is described. One application for these tetraalkylammonium thiomolybdates and thiotungstates is as precursors for MoS2 and WS2 catalysts, which were used in industrial hydrodesulfurization and hydrodenitrogenation processes. The synthesized thiometallates were characterized using the spectroscopic techniques FTIR, UV and, NMR (13C NMR) for determining their chemical structures. Thermal analyses (TGA-DTA) were done to study the fragmentation and decomposition behavior of their mol. structures.
RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1996:319437 CAPLUS
DN 125:86999
TI A new approach to some 1,6-dideoxy-1,6-epithio sugars
AU Driguez, Hugues; McAuliffe, C.; Stick, Robert V.; Tilbrook, D. Matthew G.; Wiliams, Spencer J.
CS Centre Recherches Macromolecules Vegetales, CERMAV-CNRS, Grenoble, 38041, Fr.
SO Australian Journal of Chemistry (1996), 49(3), 343-348
CODEN: AJCHAS; ISSN: 0004-9425
PB Commonwealth Scientific and Industrial Research Organization

DT Journal
LA English
OS CASREACT 125:86999
AB The treatment of hexopyranosyl bromides, also activated at C 6 (Br, OTs, OMs), with H2S/HCONMe2 under basic conditions gives 1,6-dideoxy-1,6-epithio sugars, e.g. I (R = N3, X = S). An analogous treatment of one doubly activated hexopyranosyl bromide with sodium hydrogen selenide has led to a novel 1,6-dideoxy-1,6-episeleno sugars, e.g. I (R = OAc, X = Se), which displayed interesting NMR spectra. Finally, in an attempt to prepare 1,6-dideoxy 1,6-epidithio sugars, a tetraalkylammonium tetrathiomolybdate reagent was found to be the reagent of choice for converting doubly activated hexopyranosyl bromides into 1,6-dideoxy-1,6-epithio sugars.

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:sssptau125zxf

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  FEB 27   New STN AnaVist pricing effective March 1, 2006
 NEWS  4  APR 04   STN AnaVist $500 visualization usage credit offered
 NEWS  5  MAY 10   CA/CAplus enhanced with 1900-1906 U.S. patent records
 NEWS  6  MAY 11   KOREAPAT updates resume
 NEWS  7  MAY 19   Derwent World Patents Index to be reloaded and enhanced
 NEWS  8  MAY 30   IPC 8 Rolled-up Core codes added to CA/CAplus and
                   USPATFULL/USPAT2
 NEWS  9  MAY 30   The F-Term thesaurus is now available in CA/CAplus
 NEWS 10  JUN 02   The first reclassification of IPC codes now complete in
                   INPADOC
 NEWS 11  JUN 26   TULSA/TULSA2 reloaded and enhanced with new search and
                   and display fields
 NEWS 12  JUN 28   Price changes in full-text patent databases EPFULL and PCTFULL
 NEWS 13  JUl 07   Coverage of Research Disclosure reinstated in DWPI

 NEWS EXPRESS  JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  ********************************************************************
    Due to scheduled maintenance of STN on Sunday, July 9, 2006,
    some databases may not be available until 04:00 (4:00 AM)
    Eastern Daylight Time.
  ********************************************************************

* * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:48:20 ON 07 JUL 2006

=> file ca,caplus,medline,biosis,drugu,uspatfull,wpinds
'WPINDS' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
```

```
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):wpids
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.63       0.63

FILE 'CA' ENTERED AT 16:50:09 ON 07 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 16:50:09 ON 07 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 16:50:09 ON 07 JUL 2006

FILE 'BIOSIS' ENTERED AT 16:50:09 ON 07 JUL 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'DRUGU' ENTERED AT 16:50:09 ON 07 JUL 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 16:50:09 ON 07 JUL 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 16:50:09 ON 07 JUL 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

=> s tetrapropylammonium (w) tetrathiomolybdate
L1          14 TETRAPROPYLAMMONIUM (W) TETRATHIOMOLYBDATE

=> d l1 1-14 bib, ab

L1   ANSWER 1 OF 14  CA  COPYRIGHT 2006 ACS on STN
AN   142:205454  CA
TI   Preparation of amorphous sulfide sieves
IN   Siadati, Mohammad H.; Alonso, Gabriel; Chianelli, Russell R.
PA   Centro De Investigacion En Materiales Avanzados, S.C., USA
SO   U.S. Pat. Appl. Publ., 46 pp.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   US 2005032636        A1    20050210    US 2004-819480          20040407
     WO 2005031025        A2    20050407    WO 2004-US10578         20040407
     WO 2005031025        A3    20060223
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
             SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
             TD, TG
PRAI US 2003-460951P      P     20030407
```

AB The present invention involves methods and compns. for synthesizing catalysts/porous materials. In some embodiments, the resulting materials are amorphous sulfide sieves that can be mass-produced for a variety of uses. In some embodiments, methods of the invention concern any suitable precursor (such as thiomolybdate salt) that is exposed to a high pressure pre-compaction, if need be. For instance, in some cases the final bulk shape (but highly porous) may be same as the original bulk shape. The compacted/uncompacted precursor is then subjected to an open-flow hot isostatic pressing, which causes the precursor to decompose and convert to a highly porous material/catalyst.

L1 ANSWER 2 OF 14 CA COPYRIGHT 2006 ACS on STN
AN 140:139472 CA
TI Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
IN Brewer, George J.; Merajver, Sofia D.; Coucouvanis, Dimitri
PA The University of Michigan, USA; Univ Michigan
SO PCT Int. Appl., 140 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004009072	A2	20040129	WO 2003-US22914	20030723
	WO 2004009072	A3	20040408		
	WO 2004009072	B1	20040708		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2493341	AA	20040129	CA 2003-2493341	20030723
	AU 2003261222	A1	20040209	AU 2003-261222	20030723
	US 2004259945	A1	20041223	US 2003-625839	20030723
	BR 2003012845	A	20050607	BR 2003-12845	20030723
	EP 1539131	A2	20050615	EP 2003-765921	20030723
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1688303	A	20051026	CN 2003-820746	20030723
	JP 2005538093	T2	20051215	JP 2004-523295	20030723
	ZA 2005001162	A	20050905	ZA 2005-1162	20050209
	NO 2005000902	A	20050419	NO 2005-902	20050218
PRAI	US 2002-397804P	P	20020723		
	WO 2003-US22914	W	20030723		

AB Disclosed are copper-binding compds. with improved properties and methods of using such compds. in the prevention and treatment of angiogenic diseases, such as cancer. Advantages of the invention include the enhanced stability of the compds., which is achieved without reduction in efficacy. Pharmaceutical compns., therapeutic kits and combination treatment methods and uses are also provided.

L1 ANSWER 3 OF 14 CA COPYRIGHT 2006 ACS on STN
AN 139:236000 CA
TI Mesoporous carbon-containing MoS2 materials formed from the in situ decomposition of tetraalkylammonium thiomolybdates
AU Alonso, Gabriel; Berhault, Gilles; Paraguay, Francisco; Rivera, Eric; Fuentes, Sergio; Chianelli, Russell R.
CS Centro de Investigacion en Materiales Avanzados, Chihuahua, 31109, Mex.

SO Materials Research Bulletin (2003), 38(6), 1045-1055
CODEN: MRBUAC; ISSN: 0025-5408
PB Elsevier Science Ltd.
DT Journal
LA English
AB Molybdenum disulfide with unique mesoporous structure was synthesized from tetraalkylammonium thiometallate precursors in situ decomposed in a batch reactor in the presence of dibenzothiophene (DBT). The precursors used in this study were tetraalkylammonium thiomolybdates with alkyl groups ranging from Pr to octyl. Molybdenum disulfide thus prepared presents high surface area (from 255 up to 329 m2/g), high content of carbon (C/Mo=2.7-4.0) and type IV nitrogen adsorption-desorption isotherms when decomposed from tetrahexyl-, tetraheptyl- or tetraoctylammonium thiomolybdates. The as-formed materials are poorly crystallized with a very weak intensity of the (0 0 2) peak of the 2H-MoS2 structure. Such diffraction patterns are characteristic of exfoliated samples. Characterization by TEM shows a disordered layered structure with no long range order for the MoS2 catalysts. Therefore, the nature of the alkyl group in the precursor affects both the surface area and the pore size distribution of the final MoS2 catalysts with a progressive morphol. modification up to a mesoporous organization.
RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 4 OF 14 CA COPYRIGHT 2006 ACS on STN
AN 135:146200 CA
TI Synthesis and characterization of tetraalkylammonium thiomolybdates and thiotungstates in aqueous solution
AU Alonso, G.; Berhault, G.; Chianelli, R. R.
CS Departamento de Catalisis, Centro de Investigacion en Materiales Avanzados, Chihuahua, 31109, Mex.
SO Inorganica Chimica Acta (2001), 316(1,2), 105-109
CODEN: ICHAA3; ISSN: 0020-1693
PB Elsevier Science S.A.
DT Journal
LA English
OS CASREACT 135:146200
AB In this work is reported a method for the preparation of (R4N)2MS4 (R = Pr, Oct and M = Mo, W) in aqueous solution The rapid substitution of (NH4) salts with [(Pro)4N] and [(Oct)4N] via reaction with (Pro)4NBr and (Oct)4NBr is described. Characterization of the thiomolybdates and thiotungstates was performed using FTIR, UV-visible spectroscopies and TGA (TG-DTA).
RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 5 OF 14 CA COPYRIGHT 2006 ACS on STN
AN 117:263533 CA
TI Molecular architecture of copper(I) thiometallate complexes. Example of a cubane with an extra face, (NPr4)3[MS4Cu4Cl5] (M = molybdenum, tungsten)
AU Jeannin, Yves; Secheresse, Francis; Bernes, Sylvain; Robert, Francis
CS Lab. Chim. Met. Transit., Univ. Pierre et Marie Curie, Paris, 75252, Fr.
SO Inorganica Chimica Acta (1992), 198-200, 493-505
CODEN: ICHAA3; ISSN: 0020-1693
DT Journal
LA English
AB The various structures obtained by addition of Cu(I) to MS42- (M = Mo, W) are described and illustrated by examples recently reported in the literature. The preparation and structural characterization of (NPr4)3[MS4Cu4Cl5] are given together with the connections which exist between open and closed cubane structures.

L1 ANSWER 6 OF 14 CA COPYRIGHT 2006 ACS on STN
AN 116:50301 CA
TI Heterobimetallic aggregates of copper(I) with thiotungstate and

-molybdate. Cation effect in aggregation of MS4Cu4Cl4 units, a crystallographic study
AU Secheresse, Francis; Bernes, Sylvain; Robert, Francis; Jeannin, Yves
CS Lab. Chim. Metaux Transition, Univ. Pierre et Marie Curie, Paris, 75252, Fr.
SO Journal of the Chemical Society, Dalton Transactions: Inorganic Chemistry (1972-1999) (1991), (11), 2875-81
CODEN: JCDTBI; ISSN: 0300-9246
DT Journal
LA English
AB Reaction of [MS4]2- (M = Mo, W) with CuCl in CH2Cl2 or MeCN gives a new set of bimetallic compds. isolated with various geometries for the same 1:4:4 M:S:Cu composition Crystals of [NBu4]2[MoS4Cu4Cl4] are tetragonal, space group I.hivin.4/m, Z = 2, R = 0.058, R' = 0.056. The crystal structure reveals discrete [MoS4Cu4Cl4]2- separated in the lattice by [NBu4]+. The isostructural [NBu4]2[M/S4Cu4Cl4] (1b) was isolated and characterized: tetragonal, space group I.hivin.4/m, Z = 2. The structure of [PPh4][NPr4][MoS4Cu4Cl4] consists of a dimeric aggregate: monoclinic, space group P21/n, Z = 4, R = 0.056, R' = 0.062. [NPr4]2[WS4Cu4Cl4] is polymerized through linear chains. Crystals are triclinic, space group P.hivin.1, Z = 2, R = 0.031, R' = 0.030. The isostructural [NPr4]2[MoS4Cu4Cl4] (3a) was also characterized: triclinic, space group P.hivin.1, Z = 2. The arrangements of the mono-, di- and polymeric aggregates in the lattice are discussed in terms of the size of the counter anion. For 1b and 3a only the cell dimensions were determined

L1 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:123172 CAPLUS
DN 142:205454
TI Preparation of amorphous sulfide sieves
IN Siadati, Mohammad H.; Alonso, Gabriel; Chianelli, Russell R.
PA Centro De Investigacion En Materiales Avanzados, S.C., USA
SO U.S. Pat. Appl. Publ., 46 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005032636	A1	20050210	US 2004-819480	20040407
WO 2005031025	A2	20050407	WO 2004-US10578	20040407
WO 2005031025	A3	20060223		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-460951P P 20030407
AB The present invention involves methods and compns. for synthesizing catalysts/porous materials. In some embodiments, the resulting materials are amorphous sulfide sieves that can be mass-produced for a variety of uses. In some embodiments, methods of the invention concern any suitable precursor (such as thiomolybdate salt) that is exposed to a high pressure pre-compaction, if need be. For instance, in some cases the final bulk shape (but highly porous) may be same as the original bulk shape. The compacted/uncompacted precursor is then subjected to an open-flow hot isostatic pressing, which causes the precursor to decompose and convert to a highly porous material/catalyst.

L1 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:80492 CAPLUS
DN 140:139472
TI Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
IN Brewer, George J.; Merajver, Sofia D.; Coucouvanis, Dimitri
PA The University of Michigan, USA; Univ Michigan
SO PCT Int. Appl., 140 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004009072	A2	20040129	WO 2003-US22914	20030723
	WO 2004009072	A3	20040408		
	WO 2004009072	B1	20040708		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2493341	AA	20040129	CA 2003-2493341	20030723
	AU 2003261222	A1	20040209	AU 2003-261222	20030723
	US 2004259945	A1	20041223	US 2003-625839	20030723
	BR 2003012845	A	20050607	BR 2003-12845	20030723
	EP 1539131	A2	20050615	EP 2003-765921	20030723
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1688303	A	20051026	CN 2003-820746	20030723
	JP 2005538093	T2	20051215	JP 2004-523295	20030723
	ZA 2005001162	A	20050905	ZA 2005-1162	20050209
	NO 2005000902	A	20050419	NO 2005-902	20050218
PRAI	US 2002-397804P	P	20020723		
	WO 2003-US22914	W	20030723		

AB Disclosed are copper-binding compds. with improved properties and methods of using such compds. in the prevention and treatment of angiogenic diseases, such as cancer. Advantages of the invention include the enhanced stability of the compds., which is achieved without reduction in efficacy. Pharmaceutical compns., therapeutic kits and combination treatment methods and uses are also provided.

L1 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:425124 CAPLUS
DN 139:236000
TI Mesoporous carbon-containing MoS2 materials formed from the in situ decomposition of tetraalkylammonium thiomolybdates
AU Alonso, Gabriel; Berhault, Gilles; Paraguay, Francisco; Rivera, Eric; Fuentes, Sergio; Chianelli, Russell R.
CS Centro de Investigacion en Materiales Avanzados, Chihuahua, 31109, Mex.
SO Materials Research Bulletin (2003), 38(6), 1045-1055
CODEN: MRBUAC; ISSN: 0025-5408
PB Elsevier Science Ltd.
DT Journal
LA English
AB Molybdenum disulfide with unique mesoporous structure was synthesized from tetraalkylammonium thiometallate precursors in situ decomposed in a batch reactor in the presence of dibenzothiophene (DBT). The precursors used in

this study were tetraalkylammonium thiomolybdates with alkyl groups ranging from Pr to octyl. Molybdenum disulfide thus prepared presents high surface area (from 255 up to 329 m2/g), high content of carbon (C/Mo=2.7-4.0) and type IV nitrogen adsorption-desorption isotherms when decomposed from tetrahexyl-, tetraheptyl- or tetraoctylammonium thiomolybdates. The as-formed materials are poorly crystallized with a very weak intensity of the (0 0 2) peak of the 2H-MoS2 structure. Such diffraction patterns are characteristic of exfoliated samples. Characterization by TEM shows a disordered layered structure with no long range order for the MoS2 catalysts. Therefore, the nature of the alkyl group in the precursor affects both the surface area and the pore size distribution of the final MoS2 catalysts with a progressive morphol. modification up to a mesoporous organization.

RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:314844 CAPLUS
DN 135:146200
TI Synthesis and characterization of tetraalkylammonium thiomolybdates and thiotungstates in aqueous solution
AU Alonso, G.; Berhault, G.; Chianelli, R. R.
CS Departamento de Catalisis, Centro de Investigacion en Materiales Avanzados, Chihuahua, 31109, Mex.
SO Inorganica Chimica Acta (2001), 316(1,2), 105-109
CODEN: ICHAA3; ISSN: 0020-1693
PB Elsevier Science S.A.
DT Journal
LA English
OS CASREACT 135:146200
AB In this work is reported a method for the preparation of (R4N)2MS4 (R = Pr, Oct and M = Mo, W) in aqueous solution The rapid substitution of (NH4) salts with [(Pro)4N] and [(Oct)4N] via reaction with (Pro)4NBr and (Oct)4NBr is described. Characterization of the thiomolybdates and thiotungstates was performed using FTIR, UV-visible spectroscopies and TGA (TG-DTA).

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:663533 CAPLUS
DN 117:263533
TI Molecular architecture of copper(I) thiometallate complexes. Example of a cubane with an extra face, (NPr4)3[MS4Cu4Cl5] (M = molybdenum, tungsten)
AU Jeannin, Yves; Secheresse, Francis; Bernes, Sylvain; Robert, Francis
CS Lab. Chim. Met. Transit., Univ. Pierre et Marie Curie, Paris, 75252, Fr.
SO Inorganica Chimica Acta (1992), 198-200, 493-505
CODEN: ICHAA3; ISSN: 0020-1693
DT Journal
LA English
AB The various structures obtained by addition of Cu(I) to MS42- (M = Mo, W) are described and illustrated by examples recently reported in the literature. The preparation and structural characterization of (NPr4)3[MS4Cu4Cl5] are given together with the connections which exist between open and closed cubane structures.

L1 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:50301 CAPLUS
DN 116:50301
TI Heterobimetallic aggregates of copper(I) with thiotungstate and -molybdate. Cation effect in aggregation of MS4Cu4Cl4 units, a crystallographic study
AU Secheresse, Francis; Bernes, Sylvain; Robert, Francis; Jeannin, Yves
CS Lab. Chim. Metaux Transition, Univ. Pierre et Marie Curie, Paris, 75252, Fr.

SO Journal of the Chemical Society, Dalton Transactions: Inorganic Chemistry (1972-1999) (1991), (11), 2875-81
CODEN: JCDTBI; ISSN: 0300-9246
DT Journal
LA English
AB Reaction of [MS4]2- (M = Mo, W) with CuCl in CH2Cl2 or MeCN gives a new set of bimetallic compds. isolated with various geometries for the same 1:4:4 M:S:Cu composition Crystals of [NBu4]2[MoS4Cu4Cl4] are tetragonal, space group I.hivin.4/m, Z = 2, R = 0.058, R' = 0.056. The crystal structure reveals discrete [MoS4Cu4Cl4]2- separated in the lattice by [NBu4]+. The isostructural [NBu4]2[M/S4Cu4Cl4] (1b) was isolated and characterized: tetragonal, space group I.hivin.4/m, Z = 2. The structure of [PPh4][NPr4][MoS4Cu4Cl4] consists of a dimeric aggregate: monoclinic, space group P21/n, Z = 4, R = 0.056, R' = 0.062. [NPr4]2[WS4Cu4Cl4] is polymerized through linear chains. Crystals are triclinic, space group P.hivin.1, Z = 2, R = 0.031, R' = 0.030. The isostructural [NPr4]2[MoS4Cu4Cl4] (3a) was also characterized: triclinic, space group P.hivin.1, Z = 2. The arrangements of the mono-, di- and polymeric aggregates in the lattice are discussed in terms of the size of the counter anion. For 1b and 3a only the cell dimensions were determined

L1 ANSWER 13 OF 14 USPATFULL on STN
AN 2004:328120 USPATFULL
TI Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
IN Brewer, George J., Ann Arbor, MI, UNITED STATES
Merajver, Sofia D., Ann Arbor, MI, UNITED STATES
Coucouvanis, Dimitri, Ann Arbor, MI, UNITED STATES
PA The Regents of The University of Michigan (U.S. corporation)
PI US 2004259945 A1 20041223
AI US 2003-625839 A1 20030723 (10)
PRAI US 2002-397804P 20020723 (60)
DT Utility
FS APPLICATION
LREP shelley p m fussey, williams morgan & amerson, 10333 richmond, suite 1100, houston, TX, 77042
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 5014
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are copper-binding compounds with improved properties and methods of using such compounds in the prevention and treatment of angiogenic diseases, such as cancer. Advantages of the invention include the enhanced stability of the compounds, which is achieved without reduction in efficacy. Pharmaceutical compositions, therapeutic kits and combination treatment methods and uses are also provided.

L1 ANSWER 14 OF 14 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
AN 2004-203433 [19] WPIDS
DNC C2004-080111
TI Composition, useful to treat/prevent disease associated with aberrant vascularization e.g. wet type macular degeneration, rheumatoid arthritis and cancer, comprises a tetraalkylammonium tetrathiomolybdate compound.
DC B05
IN BREWER, G J; COUCOUVANIS, D; MERAJVER, S D; MERAJVER, S
PA (UNMI) UNIV MICHIGAN
CYC 106
PI WO 2004009072 A2 20040129 (200419)* EN 140
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH

PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AU 2003261222 A1 20040209 (200450)
US 2004259945 A1 20041223 (200504)
BR 2003012845 A 20050607 (200538)
EP 1539131 A2 20050615 (200539) EN
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV MC MK NL PT RO SE SI SK TR
NO 2005000902 A 20050419 (200540)
KR 2005025976 A 20050314 (200574)
JP 2005538093 W 20051215 (200582) 97
CN 1688303 A 20051026 (200618)
MX 2005000875 A1 20051001 (200620)
ZA 2005001162 A 20051130 (200628) 138

ADT WO 2004009072 A2 WO 2003-US22914 20030723; AU 2003261222 A1 AU 2003-261222 20030723; US 2004259945 A1 Provisional US 2002-397804P 20020723, US 2003-625839 20030723; BR 2003012845 A BR 2003-12845 20030723, WO 2003-US22914 20030723; EP 1539131 A2 EP 2003-765921 20030723, WO 2003-US22914 20030723; NO 2005000902 A WO 2003-US22914 20030723, NO 2005-902 20050218; KR 2005025976 A KR 2005-701226 20050122; JP 2005538093 W WO 2003-US22914 20030723, JP 2004-523295 20030723; CN 1688303 A CN 2003-820746 20030723; MX 2005000875 A1 WO 2003-US22914 20030723, MX 2005-875 20050121; ZA 2005001162 A ZA 2005-1162 20050209

FDT AU 2003261222 A1 Based on WO 2004009072; BR 2003012845 A Based on WO 2004009072; EP 1539131 A2 Based on WO 2004009072; JP 2005538093 W Based on WO 2004009072; MX 2005000875 A1 Based on WO 2004009072

PRAI US 2002-397804P 20020723; US 2003-625839 20030723

AB WO2004009072 A UPAB: 20040318

NOVELTY - Composition (A) comprises at least one tetraalkylammonium tetrathiomolybdate compound (I) and a pharmaceutically acceptable excipient.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a kit comprising, in at least one container, at least one compound (I) and either a second, distinct therapeutic agent (II) or a component of an assay system for determining serum ceruloplasmin levels (III).

ACTIVITY - Ophthalmological; Cytostatic; Antirheumatic; Antiarthritic, Antiangiogenic.

MECHANISM OF ACTION - None given in the source material.

USE - (A) is used for treatment/prevention of a disease associated with aberrant vascularization (preferably wet type macular degeneration, rheumatoid arthritis or cancer) in an animal (preferably a human) that has or is at risk for developing the disease (claimed).

ADVANTAGE - (I) displays increased stability and shelf life, without significant loss of solubility or therapeutic efficacy. This allows the drug to be handled pharmaceutically in bulk without exquisite attention to air exclusion The stability of (I) was studied under conditions that exacerbate instability (i.e. by leaving the drug in open Petri dishes at room temperature) using a tetrathiomolybdate preparation as control. The half life of tetrapropylammonium tetrathiomolybdate under these conditions was determined to be about 180 days whereas it was about 40 days for the control.

Dwg.0/5